Kilitch Drugs (India) Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
KILITCH · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Kilitch Drugs has submitted a quarterly certificate from its Registrar and Share Transfer Agent, MUFG Intime India Private Limited, to BSE and NSE for the quarter ended 31st March 2025. The certificate, filed under SEBI's Regulation 74(5), confirms that all securities received from depository participants for dematerialisation during the quarter were properly processed and confirmed to the depositories. It also confirms that the original physical share certificates were mutilated and cancelled after verification, and the depository names were updated in the company's register of members within the prescribed timelines. The filing is signed by Managing Director Mukund Mehta and was sent on 15th April 2025. This is a standard regulatory compliance submission with no business or operational disclosures.
No material impact on shareholders or stock price — this is a routine quarterly compliance filing that simply confirms the Registrar processed share dematerialisation requests correctly during Q4 FY25.